Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04935463 · ClinicalTrials.gov registry record
Mucormycosis in COVID-19
A clinical trial, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- 728
- Enrollment target
NCT04935463: Completed study, sponsored by Montefiore Medical Center.
NCT04935463 is a clinical trial that has completed, run by Montefiore Medical Center. The registered enrollment target is 728 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04935463 has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- 728 participants
- Enrollment target
Study Summary
The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge. There is very little known about the risk factors, patterns and complications of mucormycosis as it occurs either during the infection or treatment phase of the novel coronavirus (COVID-19). In light of this emerging epidemic within a pandemic, it is of time sensitive importance to obtain a better understanding of the risk factors and outcomes of this fatal complication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2022-03-01 |
What the finished NCT04935463 record still lists
NCT04935463 is an observational study that tracks outcomes without assigning an intervention. The registered 728 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04935463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04935463 about?
NCT04935463 is a clinical study titled "Mucormycosis in COVID-19". The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge. There is very little known about the risk factors, patterns and complications of muc...
What is the current status of trial NCT04935463?
This trial is currently completed. The enrollment target is 728 participants. The study started on 2021-05-24. Estimated completion is 2022-03-01.
Who is sponsoring clinical trial NCT04935463?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- NCT06433765 · 728 participants
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- NCT06660342 · 728 participants
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI